The Alpini Lab, led by Gianfranco Alpini, PhD, evaluates the regulation of cholangiocyte proliferation/damage during the progression of cholangiopathies, the chronic diseases that target intrahepatic cholangiocytes.
The Francis Lab, led by Heather Francis, PhD, focuses on understanding and identifying target therapies for cholangiopathies, chronic and often fatal liver diseases including primary biliary cholangitis, primary sclerosing cholangitis and cholangiocarcinoma.
The Liangpunsakul Lab, led by Suthat Liangpunsakul, MD, focuses on the identification of non-invasive biomarkers to screen for excessive alcohol use and the molecular mechanism, risk factors, and treatment for alcohol-associated liver disease (ALD).
The research program of Fanyin Meng, PhD has been instrumental in the development of novel concepts about hepatobiliary regeneration/repair and the role of ncRNA in the initiation and perpetuation of chronic liver injury, aging and liver cancer.
Research in the Yang Lab, led by Zhihong (Joe) Yang, PhD is focused on the non-coding RNA’s roles in chronic liver disease, mainly in alcohol-associated liver disease (ALD) and exploration of the role of H19 and methionine metabolism in ALD.